Abo
Mann des Monats

Die Konkurrenz

-

3 Bilder
Kim Tae-han, chief executive officer of Samsung Biologics Co., speaks during an interview in Incheon, South Korea, on Wednesday, April 19, 2017. Samsung Biologics, an arm of South Korea's biggest conglomerate, said it is in negotiations to manufacture drugs for more than 15 international pharmaceutical companies as it tries to expand in the growing industry for complex biologic medicines. Photographer: SeongJoon Cho/Bloomberg
Bloomberg
Kim Tae-han, chief executive officer of Samsung Biologics Co., speaks during an interview in Incheon, South Korea, on Wednesday, April 19, 2017. Samsung Biologics, an arm of South Korea's biggest conglomerate, said it is in negotiations to manufacture drugs for more than 15 international pharmaceutical companies as it tries to expand in the growing industry for complex biologic medicines. Photographer: SeongJoon Cho/Bloomberg
Bloomberg

Werbung

Marc N. Casper
Bloomberg
Marc N. Casper
Bloomberg
Chris Chen, chief executive officer of Wuxi Biologics Cayman Inc., poses for a photograph at the Bloomberg Invest Asia forum in Hong Kong, China, on Thursday, March 21, 2019. The forum brings together some of the biggest businesses and influential institutions. Photographer: Anthony Kwan/Bloomberg
Bloomberg
Chris Chen, chief executive officer of Wuxi Biologics Cayman Inc., poses for a photograph at the Bloomberg Invest Asia forum in Hong Kong, China, on Thursday, March 21, 2019. The forum brings together some of the biggest businesses and influential institutions. Photographer: Anthony Kwan/Bloomberg
Bloomberg

Werbung